JOUNCE THERAPEUTICS INC (JNCE)       2.34  +0.14 (+6.36%)

2.34  +0.14 (+6.36%)

US4811161011 - Common Stock - After market: 2.43 +0.09 (+3.85%)

JOUNCE THERAPEUTICS INC2.34

NASDAQ:JNCE (9/30/2022, 7:00:03 PM)+0.14 (+6.36%)

After market: 2.43 +0.09 (+3.85%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-04 2022-08-04/bmo Earnings (Next) 11-02 2022-11-02
Ins Owners 4.02% Inst Owners 79.84%
Market Cap 120.96M Shares 51.69M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 80
IPO 01-26 2017-01-26

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

JNCE Daily chart

Company Profile

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2017-01-26. The firm is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The firm has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to interrogate the cellular and molecular composition of tumors. Its program, JTX-8064, is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. JTX-8064 is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor-sensitive tumors. Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS). Pimivalimab is a clinical-stage anti-PD-1 monoclonal antibody that is being developed primarily for its use in combination with its product candidates.

Company Info

JOUNCE THERAPEUTICS INC

780 Memorial Drive

Cambridge MASSACHUSETTS 02139

P: 18572593840.0

CEO: Richard Murray

Employees: 137

Website: http://jouncetx.com/

JNCE News

News Image25 days ago - Jounce Therapeutics, Inc.Jounce Therapeutics to Participate in the Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and...

News Image2 months ago - Jounce Therapeutics, Inc.Jounce Therapeutics Reports Second Quarter 2022 Financial Results

- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - -...

News Image2 months ago - Jounce Therapeutics, Inc.Jounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and...

News Image5 months ago - Jounce Therapeutics, Inc.Jounce Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and...

JNCE Twits

Here you can normally see the latest stock twits on JNCE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example